Welcome to our dedicated page for Kiniksa Pharmaceuticals International, plc news (Ticker: KNSA), a resource for investors and traders seeking the latest updates and insights on Kiniksa Pharmaceuticals International, plc stock.
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) is a commercial-stage biopharmaceutical company dedicated to discovering, acquiring, developing, and commercializing therapeutic medicines for patients with debilitating diseases that have significant unmet medical needs. Headquartered in Hamilton, Bermuda, Kiniksa is at the forefront of developing immune-modulating assets aimed at addressing a spectrum of cardiovascular and autoimmune conditions.
The company’s clinical-stage product candidates include:
- ARCALYST (rilonacept): The first and only FDA-approved therapy for recurrent pericarditis, a debilitating inflammatory cardiovascular disease. ARCALYST is also approved for cryopyrin-associated periodic syndromes (CAPS) and deficiency of IL-1 receptor antagonist (DIRA).
- Mavrilimumab: An investigational monoclonal antibody targeting the GM-CSF receptor, currently being evaluated for its potential in treating giant cell arteritis and other rare cardiovascular diseases.
- Vixarelimab: An investigational monoclonal antibody inhibitor of signaling through OSMRβ.
- Abiprubart (formerly KPL-404): A humanized monoclonal antibody designed to inhibit the CD40-CD154 interaction, aimed at treating autoimmune diseases such as rheumatoid arthritis and Sjogren’s Disease.
Kiniksa’s robust pipeline is supported by significant financial strength. The company reported strong revenue growth with ARCALYST, achieving net product revenue of approximately $233.1 million in 2023, a 90% year-over-year increase. This financial performance provides a solid foundation for future investments in both commercial and clinical development projects.
Recent news highlights Kiniksa’s progress:
- In July 2023, Kiniksa announced plans to raise its 2023 ARCALYST sales guidance to between $220 million and $230 million, citing increased prescriber adoption and patient enrollments.
- In October 2023, the company reported third-quarter financial results and the completion of enrollment in the third cohort of the Phase 2 trial of KPL-404 in rheumatoid arthritis, with data expected in the first quarter of 2024.
- In February 2024, Kiniksa announced its plans to initiate a Phase 2b trial of abiprubart in Sjogren’s Disease in the second half of 2024, supported by robust ARCALYST revenue growth and a strong cash position.
For more information about Kiniksa and its pipeline, visit www.kiniksa.com.
Rhea-AI Summary
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) will host a conference call and live webcast on February 28, 2024, to report its Q4 and full-year 2023 financial results and recent portfolio execution. Interested individuals can access the webcast through the company's website or participate via telephone by registering. A replay will be available on Kiniksa's website post-event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
-
Rhea-AI Summary
Kiniksa Pharmaceuticals, Ltd. (KNSA) reported a 90% year-over-year growth in ARCALYST net product revenue to $233.1 million in 2023. They expect ARCALYST 2024 net product revenue to be between $360 - $380 million. Abiprubart (KPL-404) Phase 2 rheumatoid arthritis trial met the primary efficacy endpoint in Cohort 3 at the weekly dose level. Cash reserves of $206.3 million are expected to fund operations into at least 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.28%
Tags
-
Rhea-AI Summary
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) to present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.83%
Tags
News
Rhea-AI Summary
Kiniksa Pharmaceuticals reports Q3 2023 net product revenue of $64.8 million, a 94% YoY growth. KPL-404 Phase 2 rheumatoid arthritis data from Cohorts 1-3 now expected in Q1 2024. Cash reserves of $201 million expected to fund operations into at least 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.74%
Tags
-
Rhea-AI Summary
Kiniksa Pharmaceuticals to report Q3 2023 financial results and recent portfolio execution
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
-
News
Rhea-AI Summary
Kiniksa Pharmaceuticals reports Q2 2023 net product revenue of $54.5 million, increases 2023 net product revenue guidance to $220-$230 million, expects Phase 2 rheumatoid arthritis data in 1H 2024, and extends cash reserves to at least 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
30.39%
Tags
Rhea-AI Summary
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) will host a conference call and live webcast on July 25, 2023 at 8:30 a.m. Eastern Time to report its second quarter 2023 financial results and recent portfolio execution. The webcast will be accessible through the company's website. Telephone participants can register to receive a confirmation email with details on how to join the call. A replay of the event will be available on Kiniksa's website within approximately 48 hours.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.02%
Tags
-
Rhea-AI Summary
Kiniksa Pharmaceuticals to participate in fireside chat at Goldman Sachs healthcare conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.07%
Tags
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.66%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.66%
Tags
FAQ
What is the current stock price of Kiniksa Pharmaceuticals International, plc (KNSA)?
The current stock price of Kiniksa Pharmaceuticals International, plc (KNSA) is $19.21 as of January 22, 2025.
What is the market cap of Kiniksa Pharmaceuticals International, plc (KNSA)?
The market cap of Kiniksa Pharmaceuticals International, plc (KNSA) is approximately 1.3B.
What is Kiniksa Pharmaceuticals' primary focus?
Kiniksa Pharmaceuticals focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs.
What are the key products in Kiniksa's pipeline?
Key products include ARCALYST (rilonacept), Mavrilimumab, Vixarelimab, and Abiprubart (KPL-404).
What recent achievements has Kiniksa Pharmaceuticals reported?
Recent achievements include strong revenue growth with ARCALYST, increased sales guidance, and the initiation of clinical trials for abiprubart in Sjogren’s Disease.
What is ARCALYST used for?
ARCALYST is used for the treatment of recurrent pericarditis, cryopyrin-associated periodic syndromes (CAPS), and deficiency of IL-1 receptor antagonist (DIRA).
When was Kiniksa's latest financial report released?
The latest financial report was released in February 2024, covering fourth quarter and full-year 2023 results.
What is the expected revenue for ARCALYST in 2024?
Kiniksa expects ARCALYST net product revenue to be between $370 million and $390 million in 2024.
What is abiprubart (KPL-404) targeting?
Abiprubart targets the CD40-CD154 interaction, aiming to address multiple autoimmune disease pathologies.
What are some of the conditions Kiniksa is targeting with its therapies?
Conditions include recurrent pericarditis, rheumatoid arthritis, Sjogren’s Disease, and other cardiovascular and autoimmune diseases.
Where can I find more information about Kiniksa Pharmaceuticals?
More information can be found on their official website at www.kiniksa.com.
Who should be contacted for investor and media inquiries?
Rachel Frank can be contacted at (339) 970-9437 or rfrank@kiniksa.com for investor and media inquiries.
Kiniksa Pharmaceuticals International, plc
Nasdaq:KNSA
KNSA Rankings
KNSA Stock Data
1.34B
39.81M
4.1%
98.01%
4.51%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
United States of America
LONDON